Amarax 2 Special Precautions

All sulfonylurea drugs are capable of producing severe hypoglycemia which is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal or hepatic function, use with caution.
If such risk factors for hypoglycemia are present, it may be necessary to adjust the dosage of glimepiride or the entire therapy. This also applies whenever illness occurs during therapy or the patient's life-style changes.
Hypoglycemia can almost always be promptly controlled by immediate intake of sugar, e.g., in the form of glucose with them of this purpose (food or beverages containing artificial sweeteners - such as diet foods or drinks - are ineffective in controlling hypoglycemia).
During treatment with glimepiride, glucose levels in blood and urine must be checked regularly, as should, additionally, the proportion of glycated haemoglobin.
Alertness and reactions may be impaired due to hypo- or hyperglycemia, especially when beginning or after altering treatment, or when glimepiride is not taken regularly.
Caution use in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents as it can lead to hemolytic anemia.
Amarax 2 contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance should not take this medicine.
Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated, however, a risk of cross-reaction exists in patients with allergy to any of these compounds, avoid use when previous reaction has been severe.
Safety and efficacy have not been established in children.